Compare VOR & CINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VOR | CINT |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.6M | 566.6M |
| IPO Year | 2021 | 2021 |
| Metric | VOR | CINT |
|---|---|---|
| Price | $15.85 | $4.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $64.78 | $6.80 |
| AVG Volume (30 Days) | ★ 709.0K | 161.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.00 |
| Revenue Next Year | N/A | $12.62 |
| P/E Ratio | ★ N/A | $17.94 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $3.98 |
| 52 Week High | $49.95 | $7.28 |
| Indicator | VOR | CINT |
|---|---|---|
| Relative Strength Index (RSI) | 62.12 | 54.34 |
| Support Level | $11.27 | $4.93 |
| Resistance Level | $16.80 | $5.24 |
| Average True Range (ATR) | 1.23 | 0.19 |
| MACD | 0.33 | -0.02 |
| Stochastic Oscillator | 74.72 | 68.97 |
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
CI&T Inc is engaged in providing plans, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.